Picture [iito] Männer Ballett 650x80px
Document › Details

Sygnis Pharma AG. (12/6/12). "Press Release: Sygnis Announces Completion of the X-Pol Biotech Acquisition. Registration of the Transaction and the Previous Capital Reduction (Ratio 8:1) in the Commercial Register". Heidelberg.

Organisations Organisation Sygnis Pharma AG
  Today Sygnis AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard)
  Group Expedeon (Group)
  Organisation 2 X-Pol Biotech S.L
  Group Expedeon (Group)
Products Product Qualiphi® DNA polymerase
  Product 2 AX200
Index terms Index term Genetrix (ES)–Sygnis: investment, 201207–201212 acquisition of X-Pol by Sygnis via reverse merger w X-Pol holding 77.5% of Sygnis after closing
  Index term 2 Qiagen–Genetrix (ES): DNA polymerase, 201207– license excl ww for Qualiphi polymerase from X-Pol Biotech
Person Person Willinger, Peter (Apogenix 201506– CFO before Sygnis Pharma + Lion Bioscience)

> New share capital of the Company € 9,349,724

> New ISIN DE000A1RFM03

> New Ticker symbol LIO1

SYGNIS Pharma AG (Frankfurt: LIO1; ISIN: DE000A1RFM03, Prime Standard) announced today that the merger with X-Pol Biotech S.L. (X-Pol) is completed. With the approval of the Annual General Meeting on October 17, 2012 SYGNIS acquired 100% of the shares of the Spanish X-Pol by way of a capital increase against contribution in kind. This transaction is completed with the registration of the capital increase in the Commercial Register. Thus X-Pol becomes a 100% subsidiary of SYGNIS and SYGNIS' share capital is increased from € 2,103,688 to € 9,349,724. After this transaction, the former shareholders of X-Pol hold 77.5% of SYGNIS shares. The previous shareholders of SYGNIS now own 22.5% of the new company. No shares were sold in the capital market.

Before the capital increase, a reduction of SYGNIS' share capital from € 16,829,504 to € 2,103,688 by consolidation of shares in the ratio of 8:1 was executed. Thereby, eight no par value bearer shares with ISIN DE000A1E9B74 were merged into one converted no par value bearer share with the new ISIN DE000A1RFM03. Accordingly, the depositary banks have converted the individual deposits of SYGNIS shares as they were on December 5, 2012.

If a shareholder did not hold a number of shares divisible by eight, a fraction of shares, this means a partial entitlement to receive one share (ISIN DE000A1RFM11), is booked for the shareholder. In order to be converted into full rights (so-called peak regulation), a corresponding buy or sell order is required. Each required peak regulation will be executed by the respective custodian bank by close of business December 21, 2012.

The first listing on December 6, 2012 will be based on the trading price of the SYGNIS share as of December 5, 2012 and will be correspondingly increased by a factor of eight.

For further information please contact:

Peter Willinger
Tel.: +49 6221 454 836

About SYGNIS Pharma AG:

SYGNIS Pharma AG (Heidelberg, Germany) is a specialized biotech company listed in the Prime Standard of the German Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03). So far, the business focus was on the research and development of innovative therapies for the treatment of diseases of the central nervous system. After the AXIS 2 study showed no efficacy of AX200 for the treatment of acute stroke, the program was discontinued. The company is currently continuing the KIBRA project. With the acquisition of X-Pol, SYGNIS will realign. The future focus of the company will be in the field of molecular diagnostics.

About X-Pol Biotech, S.L.:

X-Pol Biotech, S.L. (Madrid, Spain) is a biotechnology company created by Prof. Luis Blanco and GENETRIX in 2008 with a focus on the development of tools and technologies for the DNA amplification and sequencing market. In July 2012 X-Pol has licensed its key product, an improved polymerase for amplifying DNA called "Qualiphi®" to Qiagen for its worldwide commercialisation.

### Disclaimer

Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###

Record changed: 2017-04-02


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Expedeon (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture [iito] No Content Marketing 650x80px

» top